According to a recent LinkedIn post from Segmed, the company is partnering with Verily, an Alphabet Inc. subsidiary, to integrate de-identified diagnostic-grade imaging and associated clinical data into Verily’s AI-native precision health platform. The post indicates that this collaboration will support secure, scalable access to real-world medical imaging data within Verily’s Pre, Exchange, and Workbench environments.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that the joint offering is designed as a self-serve research environment aimed at lowering barriers for investigators and accelerating discovery in disease areas such as breast cancer. For investors, this could signal an expansion of Segmed’s distribution and use cases in precision health, potentially enhancing its strategic positioning in the medical imaging and real-world data segments of the healthcare AI ecosystem.
The collaboration, as described, emphasizes privacy-first data stewardship and scientific rigor, aligning with tightening regulatory expectations around health data use. If successfully executed, this relationship with a major Alphabet-affiliated platform could strengthen Segmed’s credibility with pharmaceutical, provider, and research customers, and may support future revenue opportunities tied to data licensing, research collaborations, and AI-driven clinical development workflows.